Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | SVP - General Counsel | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 11,344 |
Reported balance
After 2026-08-17 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-08-17 · Grant · Acquired 11,344 · Balance 11,344 F6: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11: 3,781 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 3,782 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 18,432 |
Reported balance
After 2026-08-17 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-08-17 · Grant · Acquired 18,432 · Balance 18,432 F6: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12: 18,432 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,669 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 1,669 F6: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9: 1,669 restricted stock units vest on 8/15/2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,664 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 4,664 F6: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10: 2,332 restricted stock units vest on each of 8/15/2027 and 8/15/2028. |
| Common StockSEC Table I · non-derivative | Direct | 10,360 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 10,360 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 8,944 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 8,944 F1: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.46 · Expires 2028-08-06 | Direct | 3,460 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 3,460 F1: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.52 · Expires 2029-08-15 | Direct | 3,508 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 3,508 F1: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.76 · Expires 2030-04-03 | Direct | 3,928 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 3,928 F2: Options to purchase 982 shares vest on each of 4/3/2024, 4/3/2025, 4/3/2026 and 4/3/2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.61 · Expires 2030-08-15 | Direct | 807 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 807 F1: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.61 · Expires 2030-08-15 | Direct | 16,302 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 16,302 F3: Options to purchase 4,076 shares vest on 8/15/2024 and 8/15/2026, and options to purchase 4,075 shares vest on 8/15/2025 and 8/15/2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.91 · Expires 2034-08-15 | Direct | 13,488 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 13,488 F4: Options to purchase 3,372 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.60 · Expires 2035-08-15 | Direct | 17,897 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 17,897 F5: Options to purchase 5,966 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 5,965 shares vest on 8/15/2028. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 13,992 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 13,992 F6: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F7: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 10,012 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 10,012 F6: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
Filing footnotes · ownership attribution and instrument terms
F1: Fully exercisable.
F2: Options to purchase 982 shares vest on each of 4/3/2024, 4/3/2025, 4/3/2026 and 4/3/2027.
F3: Options to purchase 4,076 shares vest on 8/15/2024 and 8/15/2026, and options to purchase 4,075 shares vest on 8/15/2025 and 8/15/2027.
F4: Options to purchase 3,372 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
F5: Options to purchase 5,966 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 5,965 shares vest on 8/15/2028.
F6: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F7: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F8: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F9: 1,669 restricted stock units vest on 8/15/2027.
F10: 2,332 restricted stock units vest on each of 8/15/2027 and 8/15/2028.
F11: 3,781 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 3,782 restricted stock units vest on 8/17/2029.
F12: 18,432 restricted stock units vest on 8/17/2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 19, 2026 20:49 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 18,432 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000134 · form4.xml · derivative · entry 15 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,432 Underlying: Common Stock · 18,432 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12 · derivative.exercise_date: 18,432 restricted stock units vest on 8/17/2029. F12 · derivative.expiration_date: 18,432 restricted stock units vest on 8/17/2029. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:49 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 11,344 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000134 · form4.xml · derivative · entry 14 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,344 Underlying: Common Stock · 11,344 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 3,781 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 3,782 restricted stock units vest on 8/17/2029. F11 · derivative.expiration_date: 3,781 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 3,782 restricted stock units vest on 8/17/2029. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 2,332 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000116 · form4.xml · derivative · entry 16 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,664 Underlying: Common Stock · 2,332 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12 · derivative.exercise_date: 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. F12 · derivative.expiration_date: 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 1,669 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000116 · form4.xml · derivative · entry 13 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,669 Underlying: Common Stock · 1,669 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027. F9 · derivative.expiration_date: 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Disposition to issuerPerformance Restricted Stock Units · Derivative | 4,502 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000116 · form4.xml · derivative · entry 11 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,502 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F7 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 300 performance RSUs. The remainder of the performance RSUs were forfeited. F7 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 300 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000116 · form4.xml · derivative · entry 10 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,502 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F7 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 300 performance RSUs. The remainder of the performance RSUs were forfeited. F7 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 300 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Disposition to issuerPerformance Stock Option (Right to Buy) · Derivative | 12,117 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0000914190-26-000116 · form4.xml · derivative · entry 9 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 807 Underlying: Common Stock · 12,117 shares Expires not disclosed F6 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 807 performance options. The remainder of the performance options were forfeited. F6 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 807 performance options. The remainder of the performance options were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000116 · form4.xml · derivative · entry 8 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F5 · derivative.exercise_date: 49 restricted stock units vest on 8/15/2026. F5 · derivative.expiration_date: 49 restricted stock units vest on 8/15/2026. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 1,343 | $72.40 | $97,233.20 |
DisclosureSEC source: 0000914190-26-000116 · form4.xml · nonDerivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,360 Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 4,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000116 · form4.xml · nonDerivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:03 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 448 | $0.00 Strike: $47.60 | $0.00 |
DisclosureSEC source: 0000914190-26-000104 · form4.xml · derivative · entry 3 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 448 shares Expires 2026-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:03 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 344 | $71.77 | $24,688.88 |
DisclosureSEC source: 0000914190-26-000104 · form4.xml · nonDerivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,353 Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:03 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 448 | $47.60 | $21,324.80 |
DisclosureSEC source: 0000914190-26-000104 · form4.xml · nonDerivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2026 Filed May 7, 2026 21:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,400 | $0.00 Strike: $47.60 | $0.00 |
DisclosureSEC source: 0000914190-26-000089 · form4.xml · derivative · entry 3 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 448 Underlying: Common Stock · 8,400 shares Expires 2026-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 05, 2026 Filed May 7, 2026 21:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 7,055 | $56.68 | $399,877.40 |
DisclosureSEC source: 0000914190-26-000089 · form4.xml · nonDerivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,249 Read SEC document |
| May 05, 2026 Filed May 7, 2026 21:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 8,400 | $47.60 | $399,840.00 |
DisclosureSEC source: 0000914190-26-000089 · form4.xml · nonDerivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2026 Filed Apr 7, 2026 20:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 2,259 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000067 · form4.xml · derivative · entry 8 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,259 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F5 · derivative.exercise_date: 2,259 restricted stock units vest on 4/3/2026. F5 · derivative.expiration_date: 2,259 restricted stock units vest on 4/3/2026. Read SEC document |
| April 03, 2026 Filed Apr 7, 2026 20:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 740 | $53.13 | $39,316.20 |
DisclosureSEC source: 0000914190-26-000067 · form4.xml · nonDerivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,904 Read SEC document |
| April 03, 2026 Filed Apr 7, 2026 20:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 2,259 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000067 · form4.xml · nonDerivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 17,897 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001062993-25-014699 · form4.xml · derivative · entry 18 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,897 Underlying: Common Stock · 17,897 shares Expires 2035-08-15 F14 · derivative.exercise_date: Options to purchase 5,966 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 5,965 shares vest on 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 6,996 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014699 · form4.xml · derivative · entry 17 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,996 Underlying: Common Stock · 6,996 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F13 · derivative.exercise_date: 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. F13 · derivative.expiration_date: 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantPerformance Restricted Stock Units · Derivative | 13,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014699 · form4.xml · derivative · entry 16 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,992 Underlying: Common Stock · 13,992 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12 · derivative.exercise_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F12 · derivative.expiration_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 1,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014699 · form4.xml · derivative · entry 14 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,338 Underlying: Common Stock · 1,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027. F10 · derivative.expiration_date: 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 50 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014699 · form4.xml · derivative · entry 10 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49 Underlying: Common Stock · 50 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F7 · derivative.exercise_date: 49 restricted stock units vest on 8/15/2026. F7 · derivative.expiration_date: 49 restricted stock units vest on 8/15/2026. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 527 | $53.60 | $28,247.20 |
DisclosureSEC source: 0001062993-25-014699 · form4.xml · nonDerivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,385 Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014699 · form4.xml · nonDerivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 20:25 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 2,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-007136 · form4.xml · derivative · entry 8 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,259 Underlying: Common Stock · 2,260 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6 · derivative.exercise_date: 2,259 restricted stock units vest on 4/3/2026. F6 · derivative.expiration_date: 2,259 restricted stock units vest on 4/3/2026. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 20:25 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 747 | $54.86 | $40,980.42 |
DisclosureSEC source: 0001062993-25-007136 · form4.xml · nonDerivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,194 Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 20:25 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 2,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-007136 · form4.xml · nonDerivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 13,488 | $0.00 Strike: $74.91 | $0.00 |
DisclosureSEC source: 0001062993-24-015382 · form4.xml · derivative · entry 15 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,488 Underlying: Common Stock · 13,488 shares Expires 2034-08-15 F12 · derivative.exercise_date: Options to purchase 3,372 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 5,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015382 · form4.xml · derivative · entry 14 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,006 Underlying: Common Stock · 5,006 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 1,668 restricted stock units vest on 8/15/2025, and 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027. F11 · derivative.expiration_date: 1,668 restricted stock units vest on 8/15/2025, and 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantPerformance Restricted Stock Units · Derivative | 10,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015382 · form4.xml · derivative · entry 13 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,012 Underlying: Common Stock · 10,012 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F10 · derivative.expiration_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015382 · form4.xml · derivative · entry 10 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99 Underlying: Common Stock · 49 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8 · derivative.exercise_date: 49 restricted stock units vest on 8/15/2024 and 8/15/2026, and 50 restricted stock units vest on 8/15/2025 F8 · derivative.expiration_date: 49 restricted stock units vest on 8/15/2024 and 8/15/2026, and 50 restricted stock units vest on 8/15/2025 Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 15 | $74.91 | $1,123.65 |
DisclosureSEC source: 0001062993-24-015382 · form4.xml · nonDerivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,681 Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015382 · form4.xml · nonDerivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:53 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 2,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-008111 · form4.xml · derivative · entry 3 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,519 Underlying: Common Stock · 2,259 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: 2,260 restricted stock units vest on 4/3/25 and 2,259 restricted stock units vest on 4/3/26. F2 · derivative.expiration_date: 2,260 restricted stock units vest on 4/3/25 and 2,259 restricted stock units vest on 4/3/26. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:53 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 747 | $67.87 | $50,698.89 |
DisclosureSEC source: 0001062993-24-008111 · form4.xml · nonDerivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,647 Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:53 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 2,259 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-24-008111 · form4.xml · nonDerivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:17 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 15,904 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-016712 · form4.xml · derivative · entry 5 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,904 Underlying: Common Stock · 15,904 shares Expires 2030-08-15 F5 · derivative.exercise_date: Options to purchase 3,976 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:17 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 11,928 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-016712 · form4.xml · derivative · entry 4 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,928 Underlying: Common Stock · 11,928 shares Expires 2030-08-15 F4 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:17 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 4,432 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016712 · form4.xml · derivative · entry 3 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,432 Underlying: Common Stock · 4,432 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F4 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Aug 24, 2023 20:20 UTC Amendment | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 16,302 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-017082 · form4a.xml · derivative · entry 3 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,302 Underlying: Common Stock · 16,302 shares Expires 2030-08-15 F3 · shares: This grant was previously reported as options to purchase 15,904 shares. This amendment reflects the corrected number of stock options granted. F4 · derivative.exercise_date: Options to purchase 4,076 shares vest on 8/15/2024 and 8/15/2026, and options to purchase 4,075 shares vest on 8/15/2025 and 8/15/2027. Read SEC document |
| August 15, 2023 Filed Aug 24, 2023 20:20 UTC Amendment | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 148 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017082 · form4a.xml · derivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148 Underlying: Common Stock · 148 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: 49 restricted stock units vest on each of 8/15/2024 and 8/15/2026, and 50 restricted stock units vest on 8/15/2025. F2 · derivative.expiration_date: 49 restricted stock units vest on each of 8/15/2024 and 8/15/2026, and 50 restricted stock units vest on 8/15/2025. Read SEC document |
| August 15, 2023 Filed Dec 14, 2023 23:14 UTC Amendment | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 12,924 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-022602 · form4a.xml · derivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,924 Underlying: Common Stock · 12,924 shares Expires 2030-08-15 F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Dec 14, 2023 23:14 UTC Amendment | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 4,802 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022602 · form4a.xml · derivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,802 Underlying: Common Stock · 4,802 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 3,928 | $0.00 Strike: $73.76 | $0.00 |
DisclosureSEC source: 0001062993-23-008580 · form4.xml · derivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,928 Underlying: Common Stock · 3,928 shares Expires 2033-04-03 F3 · derivative.exercise_date: Options to purchase 982 shares vest on each of 4/3/24, 4/3/25, 4/3/26 and 4/3/27. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 6,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-008580 · form4.xml · derivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,778 Underlying: Common Stock · 6,778 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: 2,259 shares vest on 4/3/24, 2,260 shares vest on 4/3/25 and 2,259 shares vest on 4/3/26. F2 · derivative.expiration_date: 2,259 shares vest on 4/3/24, 2,260 shares vest on 4/3/25 and 2,259 shares vest on 4/3/26. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.